Pharmacokinetics, safety, and tolerability of dispersible and immediate-release abacavir, dolutegravir, and lamivudine tablets in children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1–2 dose-confirmation study

Autor: Brooks, Kristina M *, Kiser, Jennifer J, Ziemba, Lauren, Ward, Shawn, Rani, Yasha, Cressey, Tim R, Masheto, Gaerolwe R, Cassim, Haseena, Deville, Jaime G, Ponatshego, Ponego L, Patel, Faeezah, Aurpibul, Linda, Barnabas, Shaun L, Mustich, Iris, Coletti, Anne, Heckman, Barbara, Krotje, Chelsea, Lojacono, Mark, Yin, Dwight E, Townley, Ellen, Moye, Jack, Majji, Sai, Acosta, Edward P, Ryan, Kevin, Chandasana, Hardik, Brothers, Cynthia H, Buchanan, Ann M, Rabie, Helena, Flynn, Patricia M
Zdroj: In The Lancet HIV August 2023 10(8):e506-e517
Databáze: ScienceDirect